jueves, 2 de febrero de 2017

NIAID Funding News - February 1, 2017 | NIH: National Institute of Allergy and Infectious Diseases

NIAID Funding News - February 1, 2017 | NIH: National Institute of Allergy and Infectious Diseases

NIH: National Institute of Allergy and Infectious Diseases

February 1, 2017 NIAID Funding News

Feature Articles 

NIAID Strives To Maintain Speedy Time To Award

Several factors impact how quickly an application progresses from receipt date to summary statement to award, most significantly the institute to which and the Council round for which you apply.

Opportunities and Resources

Study Immune Response Role of Natural Killer Cells in HIV-1 Vaccine Design

Through a new R01 funding opportunity announcement, NIAID seeks novel approaches to harness natural killer cell immunoregulatory functions in HIV-1 vaccine design and enhance protective HIV-1 specific adaptive immune responses.

HIV Vaccine Researchers: A Funding Opportunity for Your Consideration

Gaining a deeper understanding of the underlying immune mechanism of vaccine protection is vital to improving the efficacy of vaccines, the most promising long-term method of controlling the HIV/AIDS epidemic.

Study HIV-1 Infection of the Central Nervous System

Get up to five years of R01 funds to study pathogenic mechanisms involved in HIV-1 induced central nervous system dysfunction.

In The News

Notes on Implementation of Final-RPPR

We want to emphasize a few details about implementation of the new policy.

News Briefs

Advice Corner

Caution: Roles Determine Eligibility and Other Requirements

The scientific community uses many terms to describe different roles on a project. However, some terms aren’t used by NIH or are terms that cause confusion.

Reader Questions

New Funding Opportunities

See other announcements at Opportunities & Announcements.
Send suggestions or comments to deaweb@niaid.nih.gov.

No hay comentarios:

Publicar un comentario